- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Acyl Group.
Displaying page 1 of 1.
EudraCT Number: 2019-002283-27 | Sponsor Protocol Number: 1812VA323 | Start Date*: 2020-03-18 | |||||||||||
Sponsor Name:Shionogi B.V. | |||||||||||||
Full Title: A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose selection study of S-600918 in patients with refractory chronic cough | |||||||||||||
Medical condition: Refractory chronic cough | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001632-28 | Sponsor Protocol Number: GENTLE | Start Date*: 2023-10-24 |
Sponsor Name:Rijnstate | ||
Full Title: Ghrelin in anterior circulation stroke and EVT | ||
Medical condition: acute ischemic stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002392-35 | Sponsor Protocol Number: KRT-232-113 | Start Date*: 2021-02-05 | |||||||||||
Sponsor Name:Kartos Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor... | |||||||||||||
Medical condition: Relapsed/Refractory Myelofibrosis and Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BG (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003109-73 | Sponsor Protocol Number: TL-895-203 | Start Date*: 2021-02-15 | |||||||||||
Sponsor Name:Telios Pharma, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML) | |||||||||||||
Medical condition: Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004699-16 | Sponsor Protocol Number: KRT-232-117 | Start Date*: 2021-03-15 | |||||||||||||||||||||
Sponsor Name:Kartos Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukem... | |||||||||||||||||||||||
Medical condition: Phase 1b and Phase 2 Arms A and B: Adults with tumor protein 53 wild type (TP53wt) Philadelphia chromosome positive (Ph+) CML in chronic phase who are refractory or intolerant to ≥ 2 prior TKIs and... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Ongoing) HU (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001672-38 | Sponsor Protocol Number: KRT-232-102 | Start Date*: 2018-12-10 | |||||||||||
Sponsor Name:Kartos Therapeutics, Inc. | |||||||||||||
Full Title: A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemi... | |||||||||||||
Medical condition: Phlebotomy-dependent polycythemia vera. Polycythemia Vera (PV) is classified as a myeloproliferative neoplasm (MPN). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Prematurely Ended) ES (Ongoing) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002179-91 | Sponsor Protocol Number: MLE4901-101 | Start Date*: 2017-01-17 | |||||||||||
Sponsor Name:Millendo Therapeutics, Inc. | |||||||||||||
Full Title: A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS) | |||||||||||||
Medical condition: Polycystic Ovary Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004554-29 | Sponsor Protocol Number: KRT-232-109 | Start Date*: 2020-07-24 | |||||||||||||||||||||||||||||||
Sponsor Name:Kartos Therapeutics, Inc. | |||||||||||||||||||||||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or... | |||||||||||||||||||||||||||||||||
Medical condition: Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) DE (Completed) BG (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) HU (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001530-19 | Sponsor Protocol Number: KRT-232-112 | Start Date*: 2021-10-27 | |||||||||||||||||||||
Sponsor Name:Kartos Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC) | |||||||||||||||||||||||
Medical condition: Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) DE (Completed) HU (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.